# Trastuzumab Administered Concurrently or Sequentially to Anthracycline-containing Adjuvant Regimen for Breast Cancer

> **NCT01413828** · PHASE2,PHASE3 · COMPLETED · sponsor: **Peking Union Medical College Hospital** · enrollment: 201 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** concurrent
- **DRUG:** sequential

## Key facts

- **NCT ID:** NCT01413828
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-05
- **Primary completion:** 2016-08
- **Final completion:** 2016-08
- **Target enrollment:** 201 (ACTUAL)
- **Last updated:** 2016-08-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01413828

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01413828, "Trastuzumab Administered Concurrently or Sequentially to Anthracycline-containing Adjuvant Regimen for Breast Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01413828. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*